awmsg logo



voriconazole (Vfend®)


Reference No. 1528

Publication date:
31/10/2014


Appraisal information

voriconazole (Vfend®) 50 mg film-coated tablet
voriconazole (Vfend®) 200 mg film-coated tablet
voriconazole (Vfend®) 200 mg powder for solution for infusion
voriconazole (Vfend®) 200 mg powder and solvent for solution for infusion
voriconazole (Vfend®) 40 mg/ml powder for oral suspension


Company: Pfizer Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 30/10/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, voriconazole (Vfend®) cannot be endorsed for use within NHS Wales as prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant recipients.
Statement of Advice (SOA)
Download